HCID 21073153, 화합물 → HCID 21073644, 화합물

HRID 1373636노트

반응식

HRID 1373636 반응식
Cl.[O:2]1[CH2:8][CH2:7][CH2:6][O:5][C:4]2[C:9]([N:13]3[CH2:18][CH2:17][NH:16][CH2:15][CH2:14]3)=[CH:10][CH:11]=[CH:12][C:3]1=2.[O:19]=[C:20]1[NH:29][C:28]2[N:27]=[C:26]([O:30][CH2:31][CH2:32][CH2:33][CH:34]=O)[CH:25]=[CH:24][C:23]=2[CH2:22][CH2:21]1>>[O:2]1[CH2:8][CH2:7][CH2:6][O:5][C:4]2[C:9]([N:13]3[CH2:14][CH2:15][N:16]([CH2:34][CH2:33][CH2:32][CH2:31][O:30][C:26]4[N:27]=[C:28]5[C:23]([CH2:22][CH2:21][C:20](=[O:19])[NH:29]5)=[CH:24][CH:25]=4)[CH2:17][CH2:18]3)=[CH:10][CH:11]=[CH:12][C:3]1=2

참가 물질

3

반응물 2

HCID 21073153HCID 21073153, 화합물HCID 210733774-((7-Oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)oxy)butanal

생성물 1

HCID 21073644HCID 21073644, 화합물

실험 절차

In a manner similar to that of other examples above, 1-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-6-yl)-piperazine hydrochloride (J. Med. Chem. 1988, 31, 1934–1940) was coupled by reductive amination to 4-(7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yloxy)-butyraldehyde followed by typical workup and purification to give the intermediate compound. MS: APCI: M+1: 453.6 (Exact Mass: 452.55).

후처리

  1. customfollowed by typical workup and purification
  2. customto give the intermediate compound

출처 및 근거

ORD 기록
ord-171b4e8a86b44574ad96288f85ce0206
출처 데이터셋
uspto-grants-2007_01
특허 번호
US07160888B2

반응 노트

불러오는 중…